Rezolute Inc (RZLT) - Total Liabilities
Based on the latest financial reports, Rezolute Inc (RZLT) has total liabilities worth $10.63 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore RZLT year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Rezolute Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Rezolute Inc's total liabilities have evolved over time, based on quarterly financial data. See RZLT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Rezolute Inc Competitors by Total Liabilities
The table below lists competitors of Rezolute Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Top Bright Holding Co Ltd
TW:8499
|
Taiwan | NT$4.10 Billion |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$16.88 Million |
|
AIM Industrial Growth Freehold and Leasehold Real Estate Investment Trust
BK:AIMIRT
|
Thailand | ฿5.63 Billion |
|
Moury Construct SA
BR:MOUR
|
Belgium | €100.34 Million |
|
Bear Creek Mining Corporation
V:BCM
|
Canada | CA$182.62 Million |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩20.08 Billion |
|
China Lilang Limited
F:5LX
|
Germany | €2.43 Billion |
|
KNEAT.COM INC.
F:FOBK
|
Germany | €56.74 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Rezolute Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RZLT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rezolute Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rezolute Inc (2012–2025)
The table below shows the annual total liabilities of Rezolute Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.36 Million | +13.88% |
| 2024-06-30 | $11.73 Million | +55.44% |
| 2023-06-30 | $7.55 Million | +155.99% |
| 2022-06-30 | $2.95 Million | -82.14% |
| 2021-06-30 | $16.51 Million | +358.61% |
| 2020-06-30 | $3.60 Million | -65.71% |
| 2019-06-30 | $10.50 Million | +62.45% |
| 2018-06-30 | $6.46 Million | +207.65% |
| 2017-06-30 | $2.10 Million | -1.39% |
| 2016-06-30 | $2.13 Million | -3.57% |
| 2015-06-30 | $2.21 Million | +121.40% |
| 2014-06-30 | $997.92K | -81.05% |
| 2013-06-30 | $5.27 Million | +123.38% |
| 2012-06-30 | $2.36 Million | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more